Beijing DHH Law Firm Assisted Xynomic Pharmaceuticals, Inc. to Complete Its “Series B” Round Financing from NLVC
Release time：2018-06-15 11:06
On 1st June, 2018, Xynomic Pharmaceuticals, Inc. announced that it had completed the “Series B” round financing of USD 50 million from Northern Light Venture Capital (NLVC), Zhongshan Bison Healthcare Capital Co., Ltd, and Hankim Unique Co., Ltd. Mr. Yuan Yao and his team from Beijing DHH Law Firm provided the completed legal service for the financing project and drafted relevant legal documents in both Chinese and English.
Xynomic Pharmaceuticals, Inc. is a US bio-pharmaceutical company focused on licensing, developing and commercializing oncology related new drugs.